Atara biotherapeutics presents new long-term overall survival data from a combined analysis of phase 2 tab-cel® studies for epstein-barr virus-driven post-transplant lymphoproliferative disease at the ebmt 2021 annual meeting

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a pioneer in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced a combined long-term overall survival (os) analysis from three clinical studies of tabelecleucel (tab-cel®) in patients with epstein-barr virus-driven post-transplant
ATRA Ratings Summary
ATRA Quant Ranking